556 related articles for article (PubMed ID: 19369454)
1. Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study.
Lee SJ; Chang H; Yazici Y; Greenberg JD; Kremer JM; Kavanaugh A
J Rheumatol; 2009 Aug; 36(8):1611-7. PubMed ID: 19369454
[TBL] [Abstract][Full Text] [Related]
2. Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry.
Hetland ML; Lindegaard HM; Hansen A; Pødenphant J; Unkerskov J; Ringsdal VS; Østergaard M; Tarp U
Ann Rheum Dis; 2008 Jul; 67(7):1023-6. PubMed ID: 18272669
[TBL] [Abstract][Full Text] [Related]
3. Current tumor necrosis factor-alpha inhibitor use is associated with a higher probability of remissions in patients with rheumatoid arthritis.
Liang GC; Cordero M; Dyer A; Chang RW
J Rheumatol; 2005 Sep; 32(9):1662-5. PubMed ID: 16142857
[TBL] [Abstract][Full Text] [Related]
4. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study.
Genevay S; Finckh A; Ciurea A; Chamot AM; Kyburz D; Gabay C;
Arthritis Rheum; 2007 May; 57(4):679-85. PubMed ID: 17471545
[TBL] [Abstract][Full Text] [Related]
5. Changing patterns of tumor necrosis factor inhibitor use in 9074 patients with rheumatoid arthritis.
Yazici Y; Krasnokutsky S; Barnes JP; Hines PL; Wang J; Rosenblatt L
J Rheumatol; 2009 May; 36(5):907-13. PubMed ID: 19332636
[TBL] [Abstract][Full Text] [Related]
6. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors.
Chakravarty EF; Michaud K; Wolfe F
J Rheumatol; 2005 Nov; 32(11):2130-5. PubMed ID: 16265690
[TBL] [Abstract][Full Text] [Related]
7. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor.
Rioja I; Hughes FJ; Sharp CH; Warnock LC; Montgomery DS; Akil M; Wilson AG; Binks MH; Dickson MC
Arthritis Rheum; 2008 Aug; 58(8):2257-67. PubMed ID: 18668547
[TBL] [Abstract][Full Text] [Related]
8. Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy.
Pease C; Pope JE; Truong D; Bombardier C; Widdifield J; Thorne JC; Paul Haraoui B; Psaradellis E; Sampalis J; Bonner A
Semin Arthritis Rheum; 2011 Aug; 41(1):81-9. PubMed ID: 21168187
[TBL] [Abstract][Full Text] [Related]
9. Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal.
Schmajuk G; Schneeweiss S; Katz JN; Weinblatt ME; Setoguchi S; Avorn J; Levin R; Solomon DH
Arthritis Rheum; 2007 Aug; 57(6):928-34. PubMed ID: 17665462
[TBL] [Abstract][Full Text] [Related]
10. Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences.
Fautrel B; Guillemin F; Meyer O; de Bandt M; Berthelot JM; Flipo RM; Lioté F; Maillefert JF; Wendling D; Saraux A; Combe B; Le Loët X; ; ;
Arthritis Rheum; 2009 Apr; 61(4):425-34. PubMed ID: 19333993
[TBL] [Abstract][Full Text] [Related]
11. Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis.
Ljung L; Simard JF; Jacobsson L; Rantapää-Dahlqvist S; Askling J;
Arthritis Rheum; 2012 Jan; 64(1):42-52. PubMed ID: 21898355
[TBL] [Abstract][Full Text] [Related]
12. The disease activity score is not suitable as the sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic: discordance between assessment measures and limitations in questionnaire use for regulatory purposes.
Wolfe F; Michaud K; Pincus T; Furst D; Keystone E
Arthritis Rheum; 2005 Dec; 52(12):3873-9. PubMed ID: 16320335
[TBL] [Abstract][Full Text] [Related]
13. Missed opportunities in the treatment of elderly patients with rheumatoid arthritis.
Radovits BJ; Fransen J; Eijsbouts A; van Riel PL; Laan RF
Rheumatology (Oxford); 2009 Aug; 48(8):906-10. PubMed ID: 19478038
[TBL] [Abstract][Full Text] [Related]
14. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.
Askling J; Fored CM; Baecklund E; Brandt L; Backlin C; Ekbom A; Sundström C; Bertilsson L; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Klareskog L; Feltelius N
Ann Rheum Dis; 2005 Oct; 64(10):1414-20. PubMed ID: 15843454
[TBL] [Abstract][Full Text] [Related]
15. Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy.
Yazici Y; Shi N; John A
Bull NYU Hosp Jt Dis; 2008; 66(2):77-85. PubMed ID: 18537774
[TBL] [Abstract][Full Text] [Related]
16. Patterns of disease modifying antirheumatic drug use in a Spanish cohort of patients with rheumatoid arthritis.
Gonzalez-Alvaro I; Carmona L; Balsa A; Sanmarti R; Belmonte MA; Tena X;
J Rheumatol; 2003 Apr; 30(4):697-704. PubMed ID: 12672186
[TBL] [Abstract][Full Text] [Related]
17. Is the disease course of rheumatoid arthritis becoming milder? Time trends since 1985 in an inception cohort of early rheumatoid arthritis.
Welsing PM; Fransen J; van Riel PL
Arthritis Rheum; 2005 Sep; 52(9):2616-24. PubMed ID: 16142762
[TBL] [Abstract][Full Text] [Related]
18. [Differences in the management of early and established rheumatoid arthritis].
Castañeda S; Navarro F; Fernández-Carballido C; Tornero C; Marced E; Corteguera M
Reumatol Clin; 2011; 7(3):172-8. PubMed ID: 21794809
[TBL] [Abstract][Full Text] [Related]
19. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection.
Ferri C; Ferraccioli G; Ferrari D; Galeazzi M; Lapadula G; Montecucco C; Triolo G; Valentini G; Valesini G;
J Rheumatol; 2008 Oct; 35(10):1944-9. PubMed ID: 18688917
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]